A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Active, not recruiting

Plain-English translation of NCT03600883 on ClinicalTrials.gov ↗ · Source last updated March 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

Trial locations(133 sites)

United States

City of Hope National Medical Center, Duarte, California

University of California Los Angeles, Los Angeles, California

University of California at SF, San Francisco, California

Sarcoma Oncology Research Center LLC, Santa Monica, California

Rocky Mountain Cancer Centers, Denver, Colorado